Summary Previously we showed that tirapazamine (SR 4233, Win 59075) is cytotoxic towards hepatocytes under conditions of hypoxia but not in 10% or 95% oxygen and that bioreduction by DT-diaphorase or cytochrome P450 is not a major pathway. In the present study, we report that tirapazamine is highly cytotoxic to isolated rat hepatocytes maintained under 1% oxygen and the molecular cytotoxic mechanism has been elucidated. Cytotoxicity was prevented by the cytochrome P450 2EI inhibitors phenyl imidazole, isoniazid, isopropanol or ethanol, suggesting that cytochrome P450 2EI catalysed tirapazamine reductive bioactivation. By contrast, dicoumarol, a DT-diaphorase inhibitor, markedly increased tirapazamine-induced cytotoxicity. Cytotoxicity was also inhibited in normal but not DT-diaphorase-inactivated hepatocytes by increasing cellular NADH levels with lactate or ethanol or the mitochondrial respiratory inhibitors. Evidence that oxygen activation contributed to cytotoxicity was that glutathione oxidation occurred well before cytotoxicity ensued and that tirapazamine was more cytotoxic towards catalase-or glutathione reductase-inactivated hepatocytes. Furthermore, polyphenolic antioxidants such as quercetin, caffeic acid or purpurogallin, the radical trap Tempol or the iron chelator desferrioxamine prevented tirapazamine-mediated cytotoxicity. However, the antioxidants diphenylphenylenediamine, butylated hydroxyanisole or butylated hydroxytoluene did not prevent cytotoxicity and malonaldehyde formation was not increased, suggesting that lipid peroxidation was not important. The above results suggest that DT-diaphorase detoxifies tirapazamine whereas reduced cytochrome P450 reduces tirapazamine to a nitrogen oxide anion radical which forms cytotoxic reactive oxygen species as a result of redox cycling.
Presently tirapazamine (3-amino-1, 2, 4-benzotriazine-1,4-di-N-oxide) is in clinical trials as a potential anti-tumour agent. It has been shown to be a highly selective hypoxic cell cytotoxin (Zeman et al., 1986 (Zeman et al., , 1989 . It is also an effective anti-tumour agent in vivo in combination with radiation or compounds which enhance tumour hypoxia (Brown, 1987) . However subcapsular necrosis of the liver, necrosis of the kidney medulla and olfactory epithelium and bone marrow toxicity have been reported in rats after acute dosing with tirapazamine at 0.3 mmol kg ' (White et al., 1992) . Liver necrosis was confined to hepatocytes of the centrilobular zone (zone 3) which normally experience low oxygen tensions of 1-3% (White et al., 1992) . Recently, it has been confirmed that the toxicity of tirapazamine to Chinese hamster fibroblasts does not level off at high oxygen concentrations but continues to decrease as the oxygen concentrations increases (Koch, 1993) . The hypoxic cytotoxicity ratio (HCR) for tirapazamine is 50-200 (Zeman et al., 1986) .
The molecular mechanism of tirapazamine cytotoxicity is believed to result from reductive bioactivation to cytotoxic radical intermediate (Baker et al., 1988; Costa et al., 1989; Laderoute et al., 1988) and evidence for a nitroxide radical was obtained by electron spin resonance spectroscopy (Lloyd et al., 1991) . Enzymology studies with liver microsomes and NADPH have implicated cytochrome P450 and NADPHcytochrome P450 reductase as the major hepatic reductases responsible for the reductive bioactivation of tirapazamine (Walton and Workman, 1990; Walton et al., 1992; Riley et al., 1993) . Previously, using isolated rat hepatocytes as a non-proliferating model target cell and plasma membrane damage as the cytotoxic end point, we concluded that DTdiaphorase or reduced cytochrome P450 are not significantly involved in tirapazamine bioreduction in hypoxic hepatocytes (Silva and O'Brien, 1993) . In the following we report that tirapazamine is just as cytotoxic to hepatocytes under 1 % oxygen as was previously observed under nitrogen. Furthermore, in hepatocytes under 1 % oxygen, tirapazamine was detoxified by DT-diaphorase and activated by cytochrome P450 2E1 as a result of a redox cycling-mediated oxygen activation. We also report for the first time that hepatocyte toxicity is prevented by the ferric chelator desferrioxamine, superoxide dismutase mimics and polyphenolic antioxidants that scavenge reactive oxygen species.
Materials and methods

Chemicals
Tirapazamine was a gift from Dr AM Rauth, Ontario Cancer Institute, Toronto, Ontario, Canada. Antimycin A, 1-bromoheptane, caffeic acid, cimetidine, dicoumarol dithiothreitol (DTT), erythromycin, reduced glutathione (GSH), oxidised glutathione (GSSG), isoniazid, lactic acid, metyrapone, myxothiazol, potassium cyanide, sodium azide and Tempol were obtained from Sigma (St Louis, MO, USA). 1-Phenylimidazole, purpurogallin, quercetin and trypan blue were obtained from Aldrich (Milwaukee, WI, USA). Desferrioxamine was a gift from Ciba Geigy Canada (Toronto, Ontario, Canada) . N,N-bis(z-chloroethyl)-N-nitrosourea (BCNU) was a gift from Bristol-Myers (Syracuse, NY, USA). SKF-525A was a gift from Smith Kline Beecham (Oakville, Ontario, Canada) . Collagenase (from Clostridum histolyticum) and HEPES were purchased from BoehringerMannheim (Montreal, PQ, Canada). High-performance liquid chromatography (HPLC)-grade solvents were purchased from Calden (Georgetown, Ontario, Canada (Babson and Reed, 1978; Rossi et al., 1989) . Azide and BCNU were not cytotoxic at these concentrations over a 4 h incubation period. To inactivate various cytochrome P450 isoenzymes, SKF-525A, ethanol, isopropanol, 1-phenylimidazole, isoniazid, metyrapone, cimetidine or erythromycin was added to the cells 10 min before the start of the experiment (Netter, 1962; Wrighton et al., 1985; Quan et al., 1992; Riley et al., 1993) . To inactivate DT-diaphorase, hepatocytes were preincubated with dicoumarol (final concentration 2511M) for 10 min (Ernster et al., 1960; Rossi et al., 1989) . Various antioxidants, radical scavengers, desferrioxamine (ferric ion chelator), artificial electron acceptors, DTT or mitochondrial electron transport chain inhibitors were preincubated for 5 min before the start of the experiment. All enzyme modifiers or other inhibitors were maintained in the cell medium throughout the experiment and were not cytotoxic at the concentrations used.
Assays
Hepatocyte viability was assessed by the trypan blue dye exclusion test in a Neubaur chamber by light microscopy. Viability; was examined immediately after isolation, and at various time points during the experiment.
Total GSH and GSSG in the hepatocytes were measured by HPLC analysis in deproteinated samples (5% metaphosphoric acid) after derivatisation with iodoacetic acid and 1-fluoro-2,4-dinitrobenzene using a it-Bondapak NH2 column (Waters, Mississauga, Ontario, Canada) as described by Reed et al. (1980) . GSH and GSSG were used as external standards. A Waters model 6000A solvent-delivery system equipped with a Waters model 660 solvent programmer, a WISP 710A automatic injector and a data module was used for analysis.
Statistics Statistically significant differences between control and experimental groups were obtained using Student's t-test. The minimal level of significance chosen was P<0.05.
Results
As shown in Figure 1 , tirapazamine (190 LAM) added to hepatocytes maintained under 1% oxygen/94% nitrogen/5% carbon dioxide caused 50% cytotoxicity within a 2 h incubation period. Untreated hepatocytes retained their viability under these conditions. The effect of various cytochrome P450 inhibitors on tirapazamine-induced cytotoxicity is presented in Table I . Cytochrome P450 2E1 inhibitors I-phenylimidazole, isoniazid, isopropanol and ethanol were cytoprotective, whereas other cytochrome P450 inhibitors, metyrapone, SKF-525A, cimetidine and erythromycin, did not prevent tirapazamine-induced cytotoxicity. As shown in Figure 2 , dicoumarol, a highly effective inhibitor of DT-diaphorase, increased the tirapazamine-dependent cytotoxicity at least 2-fold. None of the cytochrome P450 inhibitors or dicoumarol affected the viability of hepatocytes in the absence of tirapazamine. The rate of tirapazamine disappearance (2.1 nmol min-' 10-6 cells) in hepatocytes under 1% oxygen was a little slower than that found under a hypoxic environment (Silva and O'Brien, 1993) .
Tirapazamine cytotoxicity was also prevented by increasing cytosolic NADH levels (Sood and O'Brien, 1994) by the addition of lactate or ethanol (Figure 2 ). This cytoprotection was prevented if hepatocyte DT-diaphorase was inhibited by dicoumarol ( Figure 2) . Cytotoxicity caused by tirapazamine was also markedly decreased by increasing hepatocyte cyto- tirapazamine (190ItM) with 100% cytotoxicity at 2 h. DTT, a disulphide reductant, prevented tirapazamineinduced hepatocyte cytotoxicity (Figure la) .
The phenolic antioxidants BHA or BHT and DPPD did not affect tirapazamine-dependent cytotoxicity (Table III) and tirapazamine did not increase malondialdehyde (thiobarbituric acid reactants) formation, indicating that little lipid peroxidation formation had occurred (results not shown). However, cytotoxicity was effectively prevented by a spin radical trap Tempol or the ferric ion chelator, desferrioxamine (Table III) . Furthermore, tirapazamine-induced cytotoxicity and GSH oxidation was also prevented by the polyphenolic antioxidants quercetin, purpurogallin and caffeic acid (Table III) .
As shown in Figure 3 , tirapazamine incubated with GSH reductase-inactivated hepatocytes caused GSH oxidation to GSSG before the cytotoxicity ensued. GSH oxidation was prevented by the polyphenolic antioxidants quercetin (Figure  3 ), purpurogallin and caffeic acid and by the ferric ion chelator desferrioxamine (results not shown). Furthermore, hepatocyte GSH oxidation to GSSG was prevented by inhibiting cytochrome P450 with phenylimidazole and enhanced by inhibiting DT-diaphorase with dicoumarol ( Figure 3 ).
Discussion
The clinical effectiveness of tirapazamine may be governed by a number of physiological and biochemical differences between hypoxic and normal tissues. Differences in oxygen tension as well as the relative reductase levels in the various zones of the liver may profoundly influence the effectiveness of the drug. In the present study we report that tirapazamine was as cytotoxic to isolated rat hepatocytes in the presence of a low oxygen concentration (1% oxygen) as reported previously under hypoxic conditions (Silva and O'Brien, 1993 readily detoxify tirapazamine radicals or reactive oxygen species (Silva and O'Brien, 1993) . Previously, we reported that cytochrome P450 reductase but not cytochrome P450 or DT-diaphorase seems to be important for tirapazamine bioactivation in hepatocytes under a hypoxic atmosphere (Silva and O'Brien, 1993 reduced cytochrome P450 2E1 is more effective than cytochrome P450 reductase at carrying out a one-electron bioreduction of tirapazamine to the tirapazamine radical which redox cycles and forms cytotoxic reactive oxygen species (ROS). Studies using rat/mouse liver microsomes or tumour cells have also shown that tirapazamine can undergo a oneelectron bioreduction by various enzymes including cytochrome P450 reductase and cyp2b, cyp2c, and/or cyp3c cytochrome P450 subfamilies (Walton et al., 1989; Cahil and White, 1990; Walton and Workman, 1990; Beiderman et al., 1991; Lloyd et al., 1991; Riley et al., 1993; Wang et al., 1993) . This generates a free radical which may exert its cytotoxic effects through DNA single-and double-strand breaks, probably as a result of hydrogen abstraction, but not by direct binding to DNA (Baker et al., 1988; Laderoute et al., 1988; Costa et al., 1989) . The centrilobular location of the hepatic necrosis induced by tirapazamine in rats (White et al., 1992) could therefore be explained by the low oxygen concentration in this liver zone (Kessler et al., 1973) . Cytochrome P450 2E1 is also located in the centrilobular zone of the liver (Anundi et al., 1993) and would be more reductive at low oxygen concentrations. Recently, reduced cytochrome P450 2B1 was found to catalyse a one-electron bioreduction of adriamycin (Goeptar et al., 1993) . DT-diaphorase inactivated hepatocytes were much more susceptible to tirapazamine under 1% oxygen than control hepatocytes. Furthermore, increasing NADH levels in hepatocytes (Sood and O'Brien, 1994) with lactate or ethanol or by partly inhibiting hepatocyte respiration with the mitochondrial electron transport chain inhibitors myxothiazol, antimycin A or cyanide prevented tirapazamine-induced cytotoxicity. Cytoprotection by lactate was also prevented by inhibting DT-diaphorase. This suggests that DT-diaphorase in intact cells detoxifies tirapazamine presumably as a result of a two-or four-electron bioreduction. We previously showed that the two electron as well as four-electron reduction products of tirapazamine, i.e. SR 4317 and SR 4330 respectively, are formed in intact hypoxic hepatocytes but are not toxic to cells. Recently, Riley and Workman (1992) showed that DT-diaphorase purified from Walker 256 rat tumour cells catalyses in vitro a direct two-and four-electron reduction of tirapazamine.
Reactive oxygen species (ROS) seem to be involved in the tirapazamine cytotoxic mechanisms(s) even at low oxygen concentrations as tirapazamine was also much more cytotoxic to catalase or glutathione reductase-inactivated hepatocytes. Furthermore, GSH oxidation to GSSG readily occurred in GSH reductase-inactivated hepatocytes well before cytotoxicity ensued. Also, GSH oxidation was enhanced when DT-diaphorase was inactivated with dicoumarol and prevented when cytochrome P450 2E1 was inhibited with phenylimidazole. Furthermore, Tempol, which can act as a radical trap or superoxide dismutase mimic (Gelven et al., 1991) or desferrioxamine, a ferric iron chelator, prevented hepatocyte cytotoxicity suggesting the involvement of ferric ion in the formation of ROS. Cytotoxicity and GSH oxidation was also prevented by the polyphenolic antioxidants quercetin, purpurogallin and caffeic acid, which scavenge superoxide radicals (Marklund and Marklund, 1974; Robak and Gryglewski, 1988) and butylated hydroxytoluene, which are excellent at preventing lipid peroxidation but poor at scavenging reactive oxygen species (Robek and Gryglewski, 1988) , were not cytoprotective. Furthermore, no malondialdehyde formation was detected, which suggests that lipid peroxidation was not critical to the tirapazamine cytotoxic mechanism and that membrane phospholipids are not important cytotoxic targets for either the tirapazamine nitroxide free radical or ROS. Membrane protein thiols may be important cytotoxic targets as a result of mixed protein disulphide formation by the intracellular GSSG formed early on in tirapazamine-induced cytotoxicity. Thus, the mixed protein disulphide reductant dithiothreitol restored GSH levels (data not shown) and prevented tirapazamine-induced cytotoxicity even when added 10 min after the addition of tirapazamine. Oxidation of membrane protein thiols by ROS to sulphenic acid would also explain why tirapazamine was much more cytotoxic to GSH-depleted hepatocytes. ROS may only be cytotoxic if generated at the membrane and would therefore require 0 30 60 90 120 diffusion of the tirapazamine radical from its site of generation by the endoplasmic reticular cytochrome P450 2E1. This b would be more likely to occur at 1% oxygen than at 10% or r.n 20% oxygen and could be another explanation for tirapazamine cytotoxicity at 1% oxygen. Taken together, the results from the present study suggest that in intact hepatocytes at 1% oxygen the bioreduction of tirapazamine by two or four electrons by DT-diaphorase is a detoxification pathway but that the one-electron bioreduction of tirapazamine by reduced cytochrome P450 results in the formation of cytotoxic reactive oxygen species as a result of futile redox cycling (Figure 4 ). Hepatocyte cytotoxicity could be prevented by cytochrome P450 2E1 inhibitors, NADHgenerating substrates, superoxide dismutase mimics, polyphenolic antioxidants or ferric chelators. Therefore, polyphenolic antioxidants or ferric chelators could prove useful therapeutically in preventing tirapazamine toxicity.
